Rob Lynch shares the fast-food chain’s growth strategies, including supply chain improvements, menu innovation and international expansion. He also discusses founder Danny Meyer’s support in advancing ...

A start-up that launched only 8 months ago has attracted the attention of Biogen, a major developer of neurological drugs. City Therapeutics will develop its namesake cityRNAs—short for cleavage ...

Biotech company Biogen (NASDAQ:BIIB) reported Q1 CY2025 results exceeding the market’s revenue expectations , with sales up 6.1% year on year to $2.43 billion. Its non-GAAP profit of $3.02 per ...

Biogen Inc.'s earnings and share price have ... We want to see tightening of belts and a "we’re all in this together" attitude, that can only ever be demonstrated through their actions.

As of writing, Keytruda has more than 41 approvals under its belt. These include several forms of melanoma ... controlled head-to-head trials to compare the drugs. Alzheimer’s: Biogen, Eisai’s Leqembi ...

“Biogen has been a foundational presence in the Massachusetts life science ecosystem for close to half a century,” said Governor Maura Healey, in a statement. “We are thrilled to see them ...

Biogen’s shares have tumbled more than 60 percent ... and Crispr Therapeutics. The belt-tightening has stalled leasing of lab space in biotech centers from Kendall Square to Boston’s Seaport ...

Biogen has bagged $250 million to advance a key pipeline prospect. Royalty Pharma is providing the cash to bankroll phase 3 development of a lupus candidate that Biogen has named in a bunch of ...

SAN FRANCISCO (Reuters) - Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional business development deals, the company's CEO ...

Biogen offers $7.22 per share to acquire Sage Therapeutics. Goldman Sachs projects Zurzuvae could reach $700 million in global sales by 2034. Ready to turn the market’s comeback into steady cash ...

Biogen Inc BIIB reported upbeat earnings for the third quarter on Wednesday. The company pisted third-quarter adjusted EPS of $4.08, down 6%, beating the consensus of $3.79. The company reported ...

Purespring launched out of Syncona in 2021 with $45m Series A funding under its belt. The company has a ‘gene search engine ... Vertex Pharmaceuticals and Biogen followed suit, inking deals with ...